



**Oasis Diagnostics Corporation - Pioneering Oral Fluid Diagnostic Solutions**

December 19<sup>th</sup> 2023

Re: CBE ID 2517 : Oral Evaluation, Dental Devices

My name is Paul Slowey and I am the CEO of Oasis Diagnostics® Corporation based in Vancouver Washington and Portland Oregon. By way of introduction, my Company is a pioneer in salivary diagnostics and, over the course of the last two decades, has developed a suite of 10 different technologies for standardized collection and testing of saliva specimens. Oasis technologies are available commercially around the globe and can be applied to the collection of saliva for just about any application, including collection of DNA, RNA, proteins, hormones, drugs of abuse, cell free DNA, cell free RNA, exosomes, etc. In addition, we have devices covering multiple population types including infants, children, adults, geriatrics and all animals from the size of a rat up to a horse with many animals in between including deer, sheep, pigs, cows, dogs, cats, macaques and even wolves!! In essence, we specialize in oral based technologies.

On a more personal level, in addition to acting as CEO of Oasis Diagnostics® Corporation, I am the Co-Chair of the Alzheimer's Association, "Salivary Working Group for Alzheimer's Disease", a global sub-group of the Alzheimer's Association organization comprising 50 or more global leaders in saliva working in the field of Alzheimer's disease diagnosis and treatment. I also hold an Honorary Professorship at Central South University in Changsha Hunan Province in China. Among my many accomplishments is the development of the first over the counter oral HIV test [OraQuick HIV 1 / 2] which can now be used in the privacy of one's home to test for the HIV virus that causes AIDS. This saliva test is commercially available and can be purchased in any pharmacy. This innovation has saved many lives in Sub-Saharan Africa and other parts of the World.

I have read in detail the information provided in the above CBE ID 2517 : Oral Evaluation, Dental Services <https://p4qm.org/measures/2517> for Prevention and Population Health, as well as information provided by the Institute for Healthcare Improvement [IHI] available at <https://www.ihl.org/improvement-areas> as far as areas for improvement in healthcare are categorized, and would like to provide some valuable comments that I believe will lead to streamlined procedures, higher patient compliance and better patient outcomes.

It is my sincere belief that the guidelines above provide for a range of activities to be carried out to assess the underlying oral health of children and vulnerable populations. The inclusion of a "screening" protocol is a critical element of this, but despite the American Dental Association's Position Statement on the subject of Salivary Diagnostics<sup>1</sup> and the rapid emergence of saliva for the diagnosis of chronic and



**Oasis Diagnostics Corporation - Pioneering Oral Fluid Diagnostic Solutions**

systemic diseases<sup>2</sup>, it appears that saliva is not specifically recommended for screening purposes. In view of the non-invasive methodology and passive nature of saliva specimen collection, this should be highly recommended for infants, children, geriatrics and other vulnerable populations. I also believe that the designation of screening should be expanded to include routine testing for Xerostomia / dry mouth, using readily available technologies [see below], especially in at-risk populations, including patients with cardiovascular disease, neurological diseases, the immunocompromised, and of course children.

We are all aware that saliva is critical for good oral health, acting to aid digestion, speech and the maintenance of a bacterial balance in the oral cavity, among many other functions and beneficial properties. The importance of measuring / monitoring saliva volume is also very important, so as an advocate for saliva and an individual infatuated by the possibility of providing the best possible technologies available to support patient health and ultimately save lives, I searched for a technology that is inexpensive, simple and can be used to monitor saliva flow and oral hydration with the possibility of self-administration in any location. During my search, I was fortunate enough to identify such a technology, which had been in development for a few years before I became aware of its' existence. The technology is known as the FishburneTabs<sup>®3</sup> and it is a very simple, paper-based technology that is placed in the mouth, over the tongue to collect saliva that is measured by means of a series of lines on the paper that "light up" depending upon the degree of oral hydration. This numeric scale can be easily digitized using a photo app. A photo of the FishburneTabs<sup>®</sup> is shown below:



FishburneTabs<sup>®</sup> Oral Hydration Technology



**Oasis Diagnostics Corporation - Pioneering Oral Fluid Diagnostic Solutions**

Based upon the unique properties of the FishburneTabs® that can provide valuable “missing” information on oral health, Oasis Diagnostics® Corporation entered into an agreement with the organization who developed the technology, Fishburne May LLC, in order to be able to offer the technology on a global basis to support clinical studies, oral hygiene, dentistry and research around the world.

Validation of the FishburneTabs® has been carried out resulting in published materials. I recommend that this technology is evaluated as a means of monitoring oral hydration as a critical element of overall health.

References:

- 1) <https://www.ada.org/resources/research/science-and-research-institute/oral-health-topics/salivary-diagnostics>
- 2) <https://adanews.ada.org/ada-news/2023/july/august-jada-explores-saliva-based-testing/>
- 3) <https://www.4saliva.com/FishburneTabs>